COMPARATIVE EFFICACY AND SAFETY OF ISATUXIMAB PLUS POMALIDOMIDE AND DEXAMETHASONE VERSUS DARATUMUMAB PLUS POMALIDOMIDE AND DEXAMETHASONE IN PATIENTS WITH MULTIPLE MYELOMA USING A MATCHING-ADJUSTED INDIRECT COMPARISON

被引：0
|
作者：
Leleu, X. [1 ]
Delea, T. [2 ]
Guyot, P. [3 ]
Moynahan, A. [2 ]
Singh, E. [4 ]
Tekle, C. [4 ]
Lin, P. [4 ]
机构：
[1] Univ Poitiers Hosp, Poitiers, France
[2] Policy Anal Inc, Brookline, MA USA
[3] Sanofi, Paris, France
[4] Sanofi, Cambridge, MA USA
来源：
VALUE IN HEALTH | 2022年 / 25卷 / 01期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
POSC34
引用
收藏
页码：S39 / S39
页数：1
相关论文
共 50 条
  • [21] Isatuximab-pomalidomide-dexamethasone versus pomalidomide-dexamethasone in patients with relapsed and refractory multiple myeloma: final overall survival analysis
    Richardson, Paul G.
    Perrot, Aurore
    San Miguel, Jesus
    Beksac, Meral
    Spicka, Ivan
    Leleu, Xavier
    Schjesvold, Fredrik
    Moreau, Philippe
    Dimopoulos, Meletios A.
    Huang, Shang-Yi
    Minarik, Jiri
    Cavo, Michele
    Prince, H. Miles
    Mace, Sandrine
    Zhang, Rick
    Dubin, Franck
    Morisse, Mony Chenda
    Anderson, Kenneth C.
    REVISTA CHILENA DE LITERATURA, 2024, (109): : 2239 - 2249
  • [22] Isatuximab-pomalidomide-dexamethasone versus pomalidomide-dexamethasone in patients with relapsed and refractory multiple myeloma: final overall survival analysis
    Richardson, Paul G.
    Perrot, Aurore
    San Miguel, Jesus
    Beksac, Meral
    Spicka, Ivan
    Leleu, Xavier
    Schjesvold, Fredrik
    Moreau, Philippe
    Dimopoulos, Meletios A.
    Huang, Shang-Yi
    Minarik, Jiri
    Cavo, Michele
    Prince, H. Miles
    Mace, Sandrine
    Zhang, Rick
    Dubin, Franck
    Morisse, Mony Chenda
    Anderson, Kenneth C.
    HAEMATOLOGICA, 2024, 109 (07) : 2239 - 2249
  • [23] Pomalidomide, Dexamethasone, and Daratumumab Versus Other Triplet Regimens in Patients with Relapsed or Refractory Multiple Myeloma: A Population-Adjusted Indirect Treatment Comparison
    Anwer, Faiz
    Lan, Tommy
    Dolph, Michael
    Moradian, Hoora
    Slaff, Samantha
    Shih, Yu-Hsuan
    Tang, Derek
    BLOOD, 2023, 142
  • [24] MonumenTAL-3: Phase 3 Trial of Talquetamab plus Daratumumab ± Pomalidomide Versus Daratumumab plus Pomalidomide plus Dexamethasone in Relapsed/Refractory Multiple Myeloma Following ≥1 Prior Line of Therapy
    Cohen, Yael C.
    Moreau, Philippe
    Tolbert, Jaszianne
    Qin, Xiang
    Ma, Xuewen
    Vieyra, Diego
    Langlois, Angelique
    Courtoux, Christelle
    Terry, William
    Pei, Lixia
    Heuck, Christoph
    Voorhees, Peter
    BLOOD, 2022, 140 : 4418 - 4419
  • [25] Indirect Comparison to Assess the Relative Efficacy of Carfilzomib plus Lenalidomide plus Dexamethasone Versus Bortezomib plus Thalidomide plus Dexamethasone: A Matching Adjusted Indirect Comparison
    Rael, Michael
    Benedict, Agnes
    Ishak, Jack
    Cadarette, Sarah
    Campioni, Marco
    Panjabi, Sumeet
    BLOOD, 2015, 126 (23)
  • [26] Efficacy and Safety of Daratumumab, Pomalidomide, and Dexamethasone (DPd) Compared to Daratumumab, Bortezomib, and Dexamethasone (DVd) in Daratumumab-Naive Relapsed Multiple Myeloma
    Afrough, Aimaz
    Atrash, Shebli
    Paul, Barry
    Ouchveridze, Evguenia
    Ahmed, Nausheen
    Mahmoudjafari, Zahra
    Bashir, Anam
    Alkharabsheh, Omar
    Hashmi, Hamza
    Abdallah, Al-Ola
    CANCERS, 2023, 15 (19)
  • [27] Indirect Treatment Comparisons of Daratumumab, Pomalidomide, and Dexamethasone Versus Daratumumab, Bortezomib, and Dexamethasone or Bortezomib and Dexamethasone in Patients with Difficult-to-Treat Relapsed/Refractory Multiple Myeloma
    He, Jianming
    Berringer, Heather
    Heeg, Bart
    Kampfenkel, Tobias
    Dwarakanathan, Harikumaran R.
    Johnston, Stephen
    Mendes, Joao
    Lam, Annette
    Bathija, Sacheeta
    Mackay, Eric
    BLOOD, 2021, 138
  • [28] Indirect Comparisons to Assess the Relative Efficacy of Carfilzomib plus Lenalidomide plus Dexamethasone Versus Panobinostat plus Bortezomib plus Dexamethasone and Bortezomib plus Dexamethasone: A Matching Adjusted Indirect Comparison
    Rael, Michael
    Benedict, Agnes
    Ishak, Jack
    Cadarette, Sarah
    Campioni, Marco
    Panjabi, Sumeet
    BLOOD, 2015, 126 (23)
  • [29] A phase 1b study of isatuximab plus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma
    Mikhael, Joseph
    Richardson, Paul
    Usmani, Saad Z.
    Raje, Noopur
    Bensinger, William
    Karanes, Chatchada
    Campana, Frank
    Kanagavel, Dheepak
    Dubin, Franck
    Liu, Qianying
    Semiond, Dorothee
    Anderson, Kenneth
    BLOOD, 2019, 134 (02) : 123 - 133
  • [30] APOLLO: Phase 3 randomized study of subcutaneous Daratumumab plus Pomalidomide and Dexamethasone (D-Pd) versus Pomalidomide and Dexamethasone (Pd) alone in patients with Relapsed/Refractory Multiple Myeloma (RRMM)
    Einsele, H.
    Dimopoulos, M.
    Terpos, E.
    Boccadoro, M.
    Delimpasi, S.
    Beksac, M.
    Katodritou, E.
    Moreau, P.
    Baldini, L.
    Symeonidis, A.
    Bila, J.
    Oriol, A.
    Mateos, M. -, V
    Orfanidis, I
    Ahmadi, T.
    Ukropec, J.
    Kampfenkel, T.
    Schecter, J.
    Qiu, Y.
    Amin, H.
    Vermeulen, J.
    Carson, R.
    Sonneveld, P.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 178 - 178
12345